Analysts Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) Price Target at $57.25

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have been given an average rating of “Moderate Buy” by the eight ratings firms that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $58.38.

Several equities research analysts have commented on HALO shares. Benchmark upped their target price on shares of Halozyme Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, June 25th. Piper Sandler downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their target price for the company from $48.00 to $51.00 in a research note on Friday, June 7th. The Goldman Sachs Group upped their target price on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research note on Monday, July 22nd. JMP Securities lowered their price objective on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating for the company in a research report on Wednesday, May 8th. Finally, Wells Fargo & Company increased their price objective on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the stock an “overweight” rating in a research report on Friday, June 7th.

Halozyme Therapeutics Trading Up 0.5 %

Shares of NASDAQ HALO opened at $56.23 on Monday. The company’s 50 day simple moving average is $50.02 and its 200 day simple moving average is $42.53. Halozyme Therapeutics has a fifty-two week low of $32.83 and a fifty-two week high of $57.08. The firm has a market capitalization of $7.16 billion, a P/E ratio of 23.24, a P/E/G ratio of 0.56 and a beta of 1.27. The company has a debt-to-equity ratio of 8.44, a current ratio of 6.64 and a quick ratio of 5.36.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.64 by $0.07. Halozyme Therapeutics had a net margin of 36.94% and a return on equity of 225.71%. The firm had revenue of $195.88 million during the quarter, compared to the consensus estimate of $201.72 million. On average, analysts predict that Halozyme Therapeutics will post 3.66 EPS for the current year.

Insider Buying and Selling

In related news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $45.38, for a total transaction of $453,800.00. Following the completion of the transaction, the senior vice president now owns 168,176 shares in the company, valued at $7,631,826.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 5,000 shares of the stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $53.93, for a total value of $269,650.00. Following the completion of the sale, the chief financial officer now owns 15,480 shares in the company, valued at $834,836.40. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $45.38, for a total transaction of $453,800.00. Following the completion of the sale, the senior vice president now owns 168,176 shares of the company’s stock, valued at approximately $7,631,826.88. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 45,000 shares of company stock worth $2,294,050. 2.40% of the stock is owned by insiders.

Institutional Trading of Halozyme Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Halozyme Therapeutics by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 13,259,514 shares of the biopharmaceutical company’s stock valued at $490,072,000 after acquiring an additional 152,870 shares during the last quarter. TD Asset Management Inc lifted its stake in shares of Halozyme Therapeutics by 28.1% during the 1st quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company’s stock worth $103,379,000 after buying an additional 557,350 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Halozyme Therapeutics by 2.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,736,122 shares of the biopharmaceutical company’s stock worth $64,167,000 after buying an additional 37,763 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Halozyme Therapeutics by 9.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,613,113 shares of the biopharmaceutical company’s stock worth $59,622,000 after buying an additional 145,879 shares during the last quarter. Finally, Stephens Investment Management Group LLC lifted its stake in shares of Halozyme Therapeutics by 4.4% during the 4th quarter. Stephens Investment Management Group LLC now owns 1,518,455 shares of the biopharmaceutical company’s stock worth $56,122,000 after buying an additional 63,748 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.